Suven Life Sciences has received four product patents. Of total, the company has received the grant of one product patent from Australia, two product patents from Japan and one product patent from Hong Kong corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 19 granted patents from Australia, 14 granted patents from Japan and 15 granted patents from Hong Kong. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
